Author: Zhang, Jian-ye; Yan, Yan-yan; Li, Jia-jun; Adhikari, Rameshwar; Fu, Li-wu
Title: PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake Cord-id: we7y0jxj Document date: 2020_5_15
ID: we7y0jxj
Snippet: Cancer has been a major global health problem due to its high morbidity and mortality. While many chemotherapy agents have been studied and applied in clinical trials or in clinic, their application is limited due to its toxic side effects and poor tolerability. Monoclonal antibodies specific to the PD-1 and PD-L1 immune checkpoints have been approved for the treatment of various tumors. However, the application of PD-1/PD-L1 inhibitors remains suboptimal and thus another strategy comes in to ou
Document: Cancer has been a major global health problem due to its high morbidity and mortality. While many chemotherapy agents have been studied and applied in clinical trials or in clinic, their application is limited due to its toxic side effects and poor tolerability. Monoclonal antibodies specific to the PD-1 and PD-L1 immune checkpoints have been approved for the treatment of various tumors. However, the application of PD-1/PD-L1 inhibitors remains suboptimal and thus another strategy comes in to our sight involving the combination of checkpoint inhibitors with other agents, enhancing the therapeutic efficacy. Various novel promising approaches are now in clinical trials, just as icing on the cake. This review summarizes relevant investigations on combinatorial therapeutics based on PD-1/PD-L1 inhibition.
Search related documents:
Co phrase search for related documents- academic hospital and lung cancer: 1
- academic hospital and lung disease: 1, 2, 3, 4
- acceptable morbidity and lung cancer: 1
- acceptable safety profile and adaptive innate: 1
- acceptable safety profile and additional study: 1
- acceptable safety profile and lung cancer: 1, 2
- acceptable safety profile and lung disease: 1, 2
- acceptable safety profile and lymphocyte antigen: 1
- acceptable safety profile and lymphocytic leukemia: 1
- acceptable safety profile and lymphocytic lymphoma: 1
- acceptable toxicity and lung cancer: 1, 2
- acceptable toxicity profile and lung cancer: 1
Co phrase search for related documents, hyperlinks ordered by date